Novogen Limited (NASDAQ:NVGN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “NOVOGEN LTD-ADR business is in the area of medicine know as degenerative diseases and disorders. Novogen is addressing this urgent area of medical need through the Novogen isoflavonoid technology platform – a platform that the Company believes offers the real prospect of not only treating, but also preventing, the onset of these common degenerative conditions. There are three divisions at Novagen: the pharmaceutical division, Marshall Edwards inc., and the consumer health division. “

Separately, ValuEngine raised shares of Novogen Limited from a “sell” rating to a “hold” rating in a report on Friday, July 14th.

Novogen Limited (NASDAQ NVGN) opened at 3.06 on Tuesday. The stock’s market cap is $14.79 million. Novogen Limited has a 1-year low of $0.80 and a 1-year high of $9.76. The stock has a 50 day moving average of $3.19 and a 200 day moving average of $1.68.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at

About Novogen Limited

Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.

Receive News & Stock Ratings for Novogen Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Limited and related stocks with our FREE daily email newsletter.